Jagsonpal Pharmaceuticals seeks shareholder approval via postal ballot to buyback up to 16 lakh equity shares at ₹250/share for ₹40 crores.
The buyback represents 2.39% of paid-up equity capital and 18.35% of aggregate paid-up capital and free reserves as at March 31, 2025.
The tender offer route is proposed; promoters holding 67.20% have confirmed non-participation; e-voting runs March 26 to April 24, 2026.
Company had free cash of ₹176 crores as of December 31, 2025; the buyback is expected to improve ROCE by approximately 400 bps.